An Open-label, Single-Arm Study to Evaluate the Safety and Rabies Virus Antibody Titers of Intramuscularly Administered Rabies Immune Globulin (Human)

Inclusion Criteria: * In good health in the judgment of the Investigator as determined by medical history, physical examination, and screening laboratory assessments. * Female of childbearing potential must have a negative result on the screening serum pregnancy test and must agree to practice contraception by a method of proven reliability (includes abstinence) for the duration of the study. Exclusion Criteria: * Pregnant or lactating females. * Clinical evidence of any significant acute or chronic disease that may interfere with successful completion of the trial. * Clinically significant history of the following: cardiovascular disease, hyperlipidemia, serious respiratory disease including bronchitis or asthma, endocrine disorder, liver disease, glaucoma, gastrointestinal disease, disorder of the reticuloendothelial system, or neurologic illness. * History of angioedema or nephrotic syndrome. * Non-controlled arterial hypertension. * Anemia at screening. * Significant proteinuria (\> 1 + on urine dipstick) and/or has a history of acute renal failure and/or severe renal impairment or a blood urea nitrogen or creatinine more than 2.5 times the upper limit of normal at screening and/or currently receiving dialysis. * Elevated liver enzymes (aspartate transaminase, alanine aminotransferase) and Gamma-glutamyl Transferase) equal to or greater than 1.5 times the upper limit at screening. * Previously received the rabies vaccine and/or rabies immune globulin. * Received infusi…